REVENUE sources

Revenue will be from 4 sources:

1.     Sale or lease of an EVestG™ unit to all Client Sectors.

2.     A Reimbursable Clinical Diagnostic Decision Support Service, 

A Diagnostic Imaging Centre will undertake the test upon referral to it by a clinician (C/f an Xray). NDx will charge a fee for signal analysis of the data from the test and for a Report to the clinician in respect of each patient tested. 

3.     CNS Drug Development Pharma/CRO

• Each Pharmaceutical company would require an individually negotiated license utilization agreement with an annual license fee and an ongoing royalty or other success fee. 

• Substantial savings in time (now approx. 15 years) and cost (now approx. $15b) could be saved by using EVestG™.

4.     Neuroscience Research institutions/University Centres

This market segment would be offered the provision of an EVestG™ unit with provision for a minimum number of tests/year and an associated annual fee.